Difference between revisions of "Pegfilgrastim (Neulasta)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (18 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates | + | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation. The Neulasta formulation involves [[Filgrastim (Neupogen)]] being covalently conjugated to monomethoxypolyethylene glycol (mPEG), increasing its half-life.<ref name="insert">[http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf Pegfilgrastim (Neulasta) package insert]</ref><ref>[[:File:Pegfilgrastim.pdf| Pegfilgrastim (Neulasta) package insert (locally hosted backup)]]</ref><ref>[https://www.neulasta.com/ Neulasta manufacturer's website]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
*"Do not administer Neulasta between 14 days before and 24 hours after administration of cytotoxic chemotherapy."<ref name="insert"></ref> | *"Do not administer Neulasta between 14 days before and 24 hours after administration of cytotoxic chemotherapy."<ref name="insert"></ref> | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf Pegfilgrastim (Neulasta) package insert]<ref name="insert"></ref> | ||
*[http://chemocare.com/bio/pegfilgrastim.asp Pegfilgrastim (Neulasta) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/pegfilgrastim.asp Pegfilgrastim (Neulasta) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/pegfilgrastim.asp Pegfilgrastim (Neulasta) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/pegfilgrastim.asp Pegfilgrastim (Neulasta) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/pegfilgrastim-patient-drug-information Pegfilgrastim (Neulasta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pegfilgrastim-patient-drug-information Pegfilgrastim (Neulasta) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/pegfilgrastim-patient-drug-information Pegfilgrastim (Neulasta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pegfilgrastim-patient-drug-information Pegfilgrastim (Neulasta) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *2022-08-22: Initial authorization | ||
| + | ==Also known as== | ||
| + | *'''Generic names:''' pegylated GCSF, pegylated G-CSF, pegylated granulocyte colony stimulating factor | ||
| + | *'''Brand names:''' G-Lasta, Neulasta, Neupopeg, Onpro | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category:Granulocyte | + | [[Category:Drugs]] |
| + | [[Category:Subcutaneous medications]] | ||
| + | [[Category:Pegylated medications]] | ||
| + | [[Category:Granulocyte colony-stimulating factors]] | ||
| + | |||
| + | [[Category:EMA approved in 2002]] | ||
| + | [[Category:FDA approved in 2002]] | ||
Latest revision as of 00:15, 6 July 2024
General information
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation. The Neulasta formulation involves Filgrastim (Neupogen) being covalently conjugated to monomethoxypolyethylene glycol (mPEG), increasing its half-life.[1][2][3]
Route: SC
Extravasation: n/a
- "Do not administer Neulasta between 14 days before and 24 hours after administration of cytotoxic chemotherapy."[1]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Patient drug information
- Pegfilgrastim (Neulasta) package insert[1]
- Pegfilgrastim (Neulasta) patient drug information (Chemocare)[4]
- Pegfilgrastim (Neulasta) patient drug information (UpToDate)[5]
History of changes in EMA indication
- 2022-08-22: Initial authorization
Also known as
- Generic names: pegylated GCSF, pegylated G-CSF, pegylated granulocyte colony stimulating factor
- Brand names: G-Lasta, Neulasta, Neupopeg, Onpro